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n a landmark article published in 2004,
Lawrence J. Lesko and Janet Woodcock, from the
United States Food and Drug Administration (FDA),
defined pharmacogenomics broadly as “the study of
inter-individual variations in whole-genome or candi-
date gene single-nucleotide polymorphism (SNP) maps,
haplotype markers and alterations in gene expression
or inactivation that might be correlated with pharma-
cological function and therapeutic response.” They
wisely stated that “translating pharmacogenomics from
bench to bedside (or from discovery to marketability)
is a multidisciplinary problem that involves addressing
philosophical, societal, cultural, behavioral and educa-
tional differences between the private and public sec-
tor, as well as issues unique to drug development, extent
of scientific expertise, interdisciplinary communication
and clinical practice.”
1
Examining the statement above, we see the phrase “phar-
macological function and therapeutic response.” This can
be dissected into two major elements: pharmacokinetics
and pharmacodynamics. We believe that it is always use-
ful to conceptualize pharmacology in terms of thinking
of what happens to a drug from when it first enters the
body to when it is disposed of (excreted).
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There has been considerable promise and hope that
pharmacogenomics will optimize existing treatments for
major depression, as well as identify novel targets for
drug discovery. Immediately after the sequencing of the
human genome, there was much hope that tremendous
progress in pharmacogenomics would rapidly be
achieved. In the past 10 years this initial enthusiasm has
been replaced by a more sober optimism, as we have
gone a long way towards the goal of guiding therapeu-
tics based on genomics. While the effort to translate dis-
covery to clinical applications is ongoing, we now have
a vast body of knowledge as well as a clear direction for-
ward. This article will provide a critical appraisal of the
state of the art in the pharmacogenomics of depression,
both in terms of pharmacodynamics and pharmacoki-
netics.      
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￿ Drug absorption
￿ Drug disposition
￿ Drug effect.
The first two processes are in the realm of pharmacoki-
netics, defined as the process by which a drug is
absorbed, distributed, metabolized, and eliminated. The
proteins involved and the genes that encode them regu-
late the velocity and amount of drug that circulates
through the body and that enters the target tissue(s).
Drug effect, in contrast, is in the realm of pharmacody-
namics, which according to Dokoumetzidis at al “is the
most complex process during the presence of the drug in
the human body. The drug can interact with various
physiological systems and thus it is not uncommon for
the pharmacodynamic response to be, in reality, nonlin-
ear and governed by mechanisms that have not been
studied extensively.”
2
Pharmacogenomics applied to depression—as well as to
all other diseases—faces a major obstacle: how to move
from research efforts to widespread clinical use. This has
two different elements: 
￿ First challenge: The quality and replicability of the
research findings. Are they robust enough to guide
clinical practice? 
￿ Second challenge: The very real gap between robust,
universally accepted research findings and changes
based on them to clinical guidelines and practice.
In the case of major depression, the two challenges above
are distributed along the domains of pharmacodynamics
and pharmacokinetics. The first challenge, related to the
replicability and robustness of research findings, is applic-
able to the pharmacodynamic side of the pharmacogene-
nomics of depression. The findings on the pharmacokinetic
side, in contrast, are for the most part universally accepted,
and face the second challenge, which is the grievous gap in
translation from solid research to clinical use (Table I).
The genetic basis of drug effects: 
pharmacodynamics
The genetic basis of drug effects is the pharmacody-
namic domain of the pharmacogenomics of antidepres-
sants. There has been considerable research in this area,
with variable and sometimes contradictory results. As
the body of evidence increases, some trends and findings
become more solidly established, while other leads turn
out to be increasingly harder to confirm.
Serotonin transporter gene promoter polymorphism
The serotonin (5-HT) transporter gene promoter poly-
morphism (5-HTTLPR) has been the most studied
genetic factor in association with antidepressant
response. This line of inquiry has an interesting history.
In 1993 Karl-Peter Lesch and colleagues published, in
Science, a paper that has been cited over 2000 times,
describing an association of anxiety-related traits with
a polymorphism in the serotonin (5-HT) transporter
gene regulatory region (5-HTTLPR).
3 Their findings
were of great interest to the field: the regulatory (pro-
moter) region of 5-HTTLPR has an insert/delete region
of 44 nucleotides. The short variant of the polymor-
phism reduces the transcriptional efficiency of the 5-
HTT gene promoter, resulting in decreased 5-HTT
expression and 5-HT uptake. Additional work showed
that this promoter has several other variants that may
affect function
4; some of those, such as rs25531, initially
thought to be located just upstream of 5-HTTLPR
5 and
an A/G SNP within the 5-HTTLPR,
6 turn out to be the
same variant, described independently by different
groups.
7
Lesch et al’s original paper has led to a body of work
on the 5-HTTLPR with 894 papers published to date,
making it the most intensively studied genetic variation
in psychiatry. Even though there are discrepant results,
the body of existing work to date appears to indicate
that high-expressing 5-HTTLPR alleles are associated
with increased serotonin transporter binding in the liv-
ing human brain.
8 A considerable level of quality of
positron emission tomography (PET) and single pho-
ton emission computed tomography (SPECT) imaging
studies is required to detect such in vivo effects of 5-
HTTLPR.
The principle of reuptake of monoamines at the synap-
tic cleft was discovered by Nobel Laureate Julius
Axelrod and described in 1961.
9,10 Most antidepressants
used today are monoamine reuptake inhibitors, and act
at the level of presynaptic transporters. Therefore, the
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Replicability and robustness  Gap from accepted findings
of findings to clinical use
Domain
Pharmacodynamics Pharmacokinetics
Genetic basis of drug effects Genetics of drug absorption
Genetics of drug disposition
Table I. Pharmacogenomics of depression.
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mote presynaptic reuptake of secreted amines, are the
most logical candidate genes in pharmacogenomic stud-
ies of antidepressant treatment. Based on the work of
Lesch and colleagues and on the fact that the selective
serotonin reputake inhibitors (SSRIs) are the most com-
monly used antidepressants, Smeraldi et al published, in
Molecular Psychiatry in 1998, a seminal paper in which
they show that those with at least one long allele of 5-
HTTLPR had a better therapeutic response to fluvox-
amine.
11This was the first published report of a pharma-
cogenetic effect of a promoter sequence on treatment
responses in all of medicine. 
That initial paper led to a novel body of work, conducted
independently by multiple groups from around the
world, addressing the specific topic of how 5-HTTLPR
variations are associated with antidepressant response.
Today, a PubMed search on 5-HTTLPR and antide-
pressants shows 106 articles. In 2006 Serretti conducted
a formal meta-analysis of published reports of the asso-
ciation of 5-HTTLPR with SSRI efficacy in depression.
Fifteen studies with data from 1435 patients qualified to
be in that meta-analysis. Three phenotypes were tested:
remission rate, response rate, and response rate within 4
weeks. There was a significant association of the s/s vari-
ant of 5-HTTLPR with remission rate (P<0.0001) and
both s/s and s/l variants with response rate (P=0.0002).
Response rate within 4 weeks was associated in both
models (P=0.003–P<0.00001).
12 In subsequent system-
atic reviews Horstmann and Binder identified 27 phar-
macogenetic studies of the association of 5-HTTLPR
and treatment response,
13 while Porcelli et al identified
58 such studies.
14The overall conclusions are as follows:
in Caucasian samples those with at least one l allele of
5-HTTLPR have a better, more accelerated response to
antidepressants. In contrast, results in East Asian popu-
lations are more heterogeneous and conflicting, with
some studies supporting better outcomes in those with
the s alleles,
15-18 other studies supporting no effects for 5-
HTTLPR,
19,20 and still other studies showing outcomes
similar to those of Western populations; ie, better anti-
depressant response associated with the l allele.
21-24
Additionally, another meta-analysis conducted by Kato
and Serretti focused on 5-HTTLPR effects on antide-
pressant-induced adverse drug reactions (ADRs).
25 Data
pooled from nine studies with 2642 subjects showed that
those with the l allele had reduced rates of ADRs (0.64,
CI: 0.49–0.82, P=0.0005). 
Other polymorphisms associated with antidepressant
response
The most recent formal meta-analysis of pharmacoge-
netic findings in depression
25 showed that, in addition to
5-HTTLPR, the following genes affect antidepressant
treatment response:
￿ Tryptophan hydroxylase 1 (TPH1) 218C/C genotype
(7 studies, 754 subjects): significantly associated with a
better response (odds ratio, OR=1.62; P=0.005), with
no heterogeneity between ethnicities
￿ Met variant within the brain-derived natriuretic factor
(BDNF) 66Val/Met polymorphism (4 studies, 490 sub-
jects): also significantly associated with a better
response OR=1.63, P=0.02).
In terms of ADRs, pooled odds-ratios (ORs) of the fol-
lowing two genetic variants were shown by Kato and
Serretti to be associated with a significant risk modulation
25:
￿ 5-HTTLPR  l (9 studies, 2642 subjects; OR=0.64,
P=0.0005)
￿ Serotonin receptor 2A (HTR2A) −1438G/G (7 stud-
ies, 801 subjects; OR=1.91, P=0.0006).
As expected, the level of significance became even
higher when the analysis was restricted only to patients
taking SSRIs (5-HTTLPR: P=0.0001, HTR2A:
P<0.0001).
Horstmann and Binder did a more descriptive but highly
detailed synthesis of existing findings.
13 They stratified
genes based on whether the aggregate of existing stud-
ies enrolled (i) more  than 2000 patients; (ii) fewer than
2000 patients; (iii) fewer than 1000 patients, but with evi-
dence of at least one independent replication; and (iv)
genes with positive, single positive association reports.
Table II summarizes their comprehensive survey of the
existing literature.
In addition to the genes listed in Table II, Horstmann and
Binder also identified the following genes, for which
there are only single, positive association reports: 5-
HT3A (serotonin receptor 3A, study N=100),
26 SLC6A3
(dopamine transporter, study N=190),
27 HSPA1A,
HSPA1L (heat shock 70 kDa protein 1A and I L, study
N=142),
28 p75 (p75 neutrophin receptor, study N=228),
29
MAO-B (monoamine oxidade B, study N = 76),
30 CRHR2
(corticotropin-releasing hormone 2, study N=159),
31
GSK3B (glycogen synthase kinase-3 beta, study N=168),
32
KCNK2 (TREK1) (potassium channel, subfamily K,
member 2, study N=751),
33 SERPINE1 (plasminogen
activator inhibitor type 1, study N=140),
34 ADRA2A
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35 CNR1
(cannabinoid receptor 1, study N=141),
36 and PSMB4,
TBX21, STAT3 (inflammation-related genes).
37
In summary, in the pharmacodynamic domain, variations
in four genes have been shown in research studies total-
ing at least 1500 people each to be associated with anti-
depressant treatment response. They are the serotonin
transporter gene promoter polymorphism (5-HTTLPR),
FK506 binding protein 5 (FKBP5), glutamate receptor,
ionotropic, kainate 4 (GRIK4), and serotonin receptor
2A (HTR2A). However, as can be seen in Table II, there
are enough conflicting results that make these findings
not yet ready for universal acceptance. A key question
that is emerging is the following: are we ready to trans-
late existing findings to the clinic, or is further investiga-
tive work still required to clarify the role of these genes
in antidepressant response before translation can occur?
Genetics of drug absorption 
and disposition: pharmacokinetics
It makes intuitive and scientific sense for us to assume
that the genetics underlying drug disposition (pharmaco-
kinetics) will contribute to biovailability at the site of the
action, where pharmacodynamic effects occur. Two types
of enzyme families are most important in this realm to
affect antidepressant bioavailability: (i) the cytochrome
P450 (CYP450) superfamily that regulates the degrada-
tion of antidepressants: and (ii) the superfamily of ATP
binding cassette (ABC) transporter enzymes that regu-
late entry of certain antidepressants from the bloodstream
into brain parenchyma, across the blood-brain barrier
(BBB). The major P-glycoprotein, a 170-KDa glycopro-
tein encoded by the ABCB1 (also known as MDR1—
multi drug resistance 1) gene, has a role in the pharma-
cogenomics of antidepressants through its effects on the
entry of antidepressant substrates (such as the tricyclics,
citalopram, venlafaxine, and paroxetine) into the brain
38,39;
however the findings in this area have been contradic-
tory.
40 In contrast, the data on the effects of CYP450
enzymes on the bioavailability of antidepressant drugs are
very well established. 
The pharmacogenetic effects of CYP450 have been
reviewed elsewhere.
41,42 Among CYP450 enzymes,
CYP2D6—and to a lesser degree CYP2C19—are the
most important for antidepressant metabolism. For that
Translational research
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Gene Positive association No association
(abbreviation) (full name) Number of studies Number of subjects Number of studies Number of subjects
Genes with replicated evidence from studies with a total N of more than 2000
FKBP5 FK506 binding protein 5 4 1524 3 1030
GRIK4 Glutamate receptor, ionotropic, kainate 4 2 2203 0 0
HTR2A Serotonin receptor 2A 8 3556 5 555
Genes with replicated evidence from studies with a total N of less than 2000
COMT Catechol-O-methyltransferase 6 834 1 334
HTR1A Serotonin receptor 1A 3 635 5 941
BDNF Brain-derived neurotrophic factor 1 3 591 2 856
TPH1 Tryptophan hydroxylase 1 5 453 4 638
GNB3 G-protein beta 3 3 684 4 630
Genes with at least one independent replication and a total N of less than 1000
TPH2 Tryptophan hydroxylase 2 1 182 1 96
CRHR1 Corticotropin releasing hormone receptor 1 2 207 1 159
MAOA Monoamine oxidase A 0 0 7 1298
DTNBP1 Dysbindin 2 251 1 293
SLCA2 Norepinephrine transporter 3 520 0 0
NR3C1 Glucocorticoid receptor 2 1063 1 98
ACE Angiotensin-converting enzyme 1 313 1 35
HTR6 Serotonin receptor 6 1 34 1 91
PD1A, PDE11A Cyclic nucleotide phosphodiesterases 2 419 1 204
Table II. Summary of data survey by Horstmann and Binder.
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43 made specific recommenda-
tions for dosage based on the effects of variants of the
genes encoding those enzymes on bioavailability of sev-
eral widely used antidepressants. The recommended
dose adjustments based on CYP2D6 function can be
seen in Figure 1; the dose adjustments based on
CYP2C19 can be seen in Figure 2. 
There is a solid scientific foundation for the recommen-
dations made Kirchheiner and colleagues, which indicate
a readiness for clinical translation in this area. Other
groups have, however, questioned whether we are
indeed ready to use in routine clinical care the testing
for CYP450 polymorphisms in adults with nonpsychotic
depression treated with SSRIs. The Evaluation of
Genomic Applications in Practice and Prevention
(EGAPP) Working Group, supported by the Centers for
Disease Control and Prevention (CDC), found insuffi-
cient evidence for a recommendation regarding the use
of CYP450 testing in adults beginning SSRI treatment
for nonpsychotic depression. The EGAPP summarized
its recommendations as follows: “In the absence of sup-
porting evidence, and with consideration of other con-
textual issues, EGAPP discourages use of CYP450 test-
ing for patients beginning SSRI treatment until further
clinical trials are completed.” This recommendation was
based on the following rationale:
The EGAPP Working Group found no evidence linking
testing for CYP450 to clinical outcomes in adults treated
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Figure 1. CYP2D6-mediated quantitative influences on pharmacokinetics of antidepressant drugs expressed as percent dose adjustments: CYP2D6
poor metabolizers (PM, white), intermediate metabolizers (IM, gray), extensive metabolizers (EM, dark gray), ultrarapid metabolizers (UM, black).
Dose adjustments were calculated according to the data given in Table II. If data on active drug moiety (consisting on active principle metabo-
lite+parent drug of active enantiomers of a racemic drug) were given, dose recommendations were based on these data only (other studies not
providing so detailed information were not incorporated). If more than one study was integrated, the weighted mean for the dose adjust-
ment was taken according to the number of poor metabolizers in each study. Data on mirtazapine, moclobemide, fluoxetine, and maprotiline
were not shown in the figure, since no dose adjustment based on CYP2D6 can be recommended at present. 
Reproduced from ref 43: Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations
to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473. Copyright © Nature Publishing Group 2004
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healthy patients report an association between genotypic
CYP450 drug metabolizer status and circulating SSRI lev-
els, this association was not supported by studies of patients
receiving ongoing SSRI treatment. Further, CYP450 geno-
types are not consistently associated with the patient out-
comes of interest, including clinical response to SSRI treat-
ment or adverse events as a result of treatment. No
evidence was available showing that the results of CYP450
testing influenced SSRI choice or dose and improved
patient outcomes, or was useful in medical, personal, or
public health decision-making. In the absence of evidence
supporting clinical utility, it is not known if potential ben-
efits from CYP450 testing will outweigh potential harms.
Potential harms may include increased cost without impact
on clinical decision making or improvement in patient out-
comes, less effective treatment with SSRI drugs, or inap-
propriate use of genotype information in the management
of other drugs metabolized by CYP450 enzymes.
44
The major issue in the domain of pharmacokinetics is
not whether the CYP450 genes have a role in the metab-
olism of antidepressants, which they do, but if sufficiently
solid evidence exists that justify the benefits of genetic
testing for them routinely in the clinic. For those bene-
fits to be documented, the EGAPP Working Group rec-
ommends “adequately powered, randomized controlled
clinical trials that compare patient outcomes when treat-
ment is informed by genotyping tests versus empirical
treatment. Because depression is prevalent and is an
important public health issue, and because SSRIs are
widely prescribed, such trials are feasible and essential
to determine best management practices with respect to
CYP450 testing.”
It is, however, challenging to obtain competitive funding
for such studies. The conundrum here is that, while such
studies are critically needed for translation of research to
practice to occur, they are not designed to test a concep-
tually novel hypothesis. Work that is not hypothesis-dri-
ven tends not to fare well in the fierce competition for
research funds, which is only getting worse.
45 In our opin-
ion it is unlikely that the necessary funding, which is
required for large, definitive translational treatment stud-
Translational research
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Figure 2. CYP2C19-mediated quantitative influences on pharmacokinetics of antidepressant drugs expressed as percentage dose adaptations: CYP2C19
poor metabolizers (PM, white), intermediate metabolizers (IM, gray), extensive metabolizers (EM, dark gray).  
Reproduced from ref 43: Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations
to the phenotype of drug response. Mol Psychiatry. 2004;9:442-473. Copyright © Nature Publishing Group 2004
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seeable future. , unless a concerted effort is made to fund
studies that are required to accelerate the translational
pathway from medical knowledge to clinical practice. We
are hopeful that such studies might fall under the domain
of the recently proposed - and much needed - National
Center for Advancing Translational Sciences (NCATS).
46
Conclusions
The gap from research to translation is still vast in the
area of pharmacogenomics of antidepressants, in spite of
over a decade of intensive work.
47-55Two major steps need
to occur before depressed patients can benefit from
genomic tools for the optimization of their treatment.
The first is that existing research findings need to be fur-
ther solidified, and current controversies and disparate
results must be understood and integrated into a univer-
sally accepted body of knowledge. That is what is the field
is currently dealing with in the domain of pharmacody-
namics—or drug effects. The second step is in the area of
bringing accepted research findings into practice. The
issue in this domain is not whether there is solid scientific
evidence; it is in the realm of cost-benefit: will genetic
testing, even though logical and rational, be indeed clin-
ically beneficial so that it ought to become part of rou-
tine clinical care? This is the locus of the translational gap
in the domain of pharmacokinetics. Overall, pursuit of a
scientific basis to choose a specific drug, maximizing ther-
apeutic effects and minimizing ADRs, is so important
that the pharmacogenomics of depression has become
a burgeoning area of research. Depression, for which we
have no biological predictors of drug response, is a key
target for advancement in the field of pharmacoge-
nomics, which has been identified by the NIH Director
Francis Collins as one of the key areas of national
research priority.
56We are cautiously hopeful that in the
current decade much progress will be achieved in devel-
oping and implementing pharmacogenomics as a trans-
lational clinical tool to improve the outcomes and reduce
the risks of antidepressant treatment. Furthermore, novel
and robust pharmacogenomic findings would represent
the next logical therapeutic targets for drug development
in depression. As examples, recent work by our group has
identified phosphodiesterases (PDE11A) and inflam-
matory mediators (PSMB4, TBX21, and STAT3) as
potential novel antidepressant targets.
3,54This way, phar-
macogenomics will not only identify predictors of
response to existing treatments, it will also have the
potential to lead to conceptually novel treatments.  ❏
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Farmacogenómica de la depresión: una eva-
luación crítica
Han sido considerables las promesas y esperanzas
respecto a que la farmacogenómica pudiera opti-
mizar los tratamientos existentes para la depresión
mayor, así como identificar nuevos blancos para el
descubrimiento de fármacos.  Inmediatamente des-
pués de la secuenciación del genoma humano hubo
grandes esperanzas en que rápidamente se alcan-
zaría un tremendo progreso en la farmacogenó-
mica. En los últimos diez años este entusiasmo ini-
cial fue reemplazado por un prudente optimismo y
se ha recorrido un largo camino hacia el objetivo de
guiar la terapéutica en base a la genómica. Así
como se sigue progresando en el esfuerzo por tra-
ducir los descubrimientos en aplicaciones clínicas
sigue progresando y actualmente se cuenta con un
gran conjunto de conocimientos así como una clara
dirección a futuro. Este artículo entregará una eva-
luación crítica del estado del arte en la farmacoge-
nómica de la depresión, tanto en términos farma-
codinámicos como farmacocinéticos.
Pharmacogénomique de la dépression : une
évaluation critique
La pharmacogénomique a soulevé promesses et
espoirs considérables d’optimiser les traitements
existants de la dépression majeure et de trouver de
nouvelles cibles pour la recherche pharmaceutique.
Le séquençage du génome humain a été immédia-
tement suivi d’espoirs sans précédents de progrès
rapides en pharmacogénomique. Cet enthousiasme
a été remplacé ces 10 dernières années par un opti-
misme modéré, bien que nous ayons parcouru un
long chemin vers les recommandations thérapeu-
tiques basées sur la génomique. La traduction des
découvertes en applications cliniques est en cours
et nous disposons maintenant de connaissances
élargies et de perspectives claires. Cet article pro-
pose une évaluation critique de l’état de l’art sur la
pharmacogénomique de la dépression, à la fois en
termes de pharmacodynamique et de pharmacoci-
nétique.
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